Hemostasis in Liver Cirrhosis and Hepatocellular Cancer
Recruiting now
Conditions studied: Hemostasis in Decompensated Liver Cirrhosis, Inflammation in Decompensated Liver Cirrhosis
In brief
Evaluating hemostasis in decompensated liver cirrhosis with novel hemostatic assays.
Key facts
- Study ID
- NCT06212635
- Run by
- Region Stockholm
- People needed
- 100
- Starts
- 2022-12-02
- Expected to finish
- 2028-12-01
- Last updated by the study team
- 2024-01-19
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Patients with decompensated liver cirrhosis
- 18 years or older.
- Healthy individuals 18 years or older will serve as controls.
You may not qualify if…
- • Extrahepatic malignancy or recurrence of such within the last year.
- Diagnosis of non-cirrhotic coagulopathy, coagulation disorder or thrombophilia prior to inclusion.
- Diagnosis of hematological disease such as hematologic malignancies, non-cirrhotic thrombocytopenia or thrombocytosis, Polycytemia Vera, hemoglobinopathies
- Previous liver transplantation.
- Transfusions the last 7 days.
- Treatment with platelet inhibitors or anticoagulant except for prophylactic dosage of LMWH. If a prophylactic dose of LMWH has been used study sampling with addition of antiFXa must be taken >12 hours after the last injection.
Where it is running
- Karolinska University Hospital — Stockholm, Huddinge, Sweden (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.